Advertisement

U.S. markets open in 4 hours 17 minutes

S&P Futures
5,969.25
+11.00(+0.18%)
Dow Futures
43,978.00
+77.00(+0.18%)
Nasdaq Futures
20,944.25
+50.25(+0.24%)
Russell 2000 Futures
2,413.40
+7.60(+0.32%)
Crude Oil
71.22
-0.47(-0.66%)
Gold
2,666.80
-9.50(-0.35%)

Synlogic, Inc. (SYBX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

1.4300

-0.0200

(-1.38%)

At close: 04:00PM EST

Loading interactive chart...

Clinical Trials Arena
Otsuka snaps up Jnana with its phenylketonuria drug for $800m
The acquisition is expected to conclude in Q3 this year and will see Otsuka adding Jnana’s Phase I/II phenylketonuria therapy to its rare disease portfolio.
GlobeNewswire
Synlogic Reports Second Quarter 2024 Financial Results
WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the second quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explor